Skip to main content
. 2020 Mar 30;24(1):55–66. doi: 10.5114/wo.2020.94726

Fig. 2.

Fig. 2

De novo and re-purposing drug development phases. Unlike the drugs that follow the conventional pathway to the pharmaceutical market, re-purposing candidates shorten the time needed to market by omitting some initial steps, which go directly into the clinical study phases (FDA – Food and Drug Administration. I, II, III – stages in the clinical development [clinical phases])